Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Erstveröffentlichung

2021

Authors

Fasching, P. A.

Link, T.

Hauke, J.

Seither, F.

Jackisch, C.

et al.

Wissenschaftlicher Artikel

Published in

Annals of Oncology ; 32 (2021), 1. - S. 49-57. - ISSN 0923-7534. - eISSN 1569-8041

Link to publication

https://dx.doi.org/10.1016/j.annonc.2020.10.471

Institutions

UKU. Klinik für Frauenheilkunde und Geburtshilfe

Subject headings

[Free subject headings]: PARP inhibitor | HER2-negative breast cancer | HRD | neoadjuvant therapy | olaparib | carboplatinum | PATHOLOGICAL COMPLETE RESPONSE | CHEMOTHERAPY | CARBOPLATIN | GEPARSIXTO | SURVIVAL | MUTATION
[DDC subject group]: DDC 610 / Medicine & health

Metadata

Show full item record